Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Company Overview - Immunic, Inc. is a biotechnology company focused on developing orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases [4] - The company's lead development program, vidofludimus calcium (IMU-838), is in phase 3 and phase 2 clinical trials for relapsing and progressive multiple sclerosis, respectively [4] - Vidofludimus calcium has demonstrated therapeutic activity in phase 2 trials for relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis [4] - Other development programs include IMU-856, targeting Sirtuin 6 (SIRT6) for gastrointestinal diseases, and IMU-381, a next-generation molecule in preclinical testing [4] Upcoming Events - Immunic will release its financial results for Q3 2024 on November 7, 2024, before the U.S. financial markets open [1] - A webcast will follow at 8:00 am ET on the same day, with registration available in advance [2] - An archived replay of the webcast will be accessible approximately one hour after completion on Immunic's website [3]